We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

66 hedge funds and large institutions have $226M invested in Protagonist Therapeutics in 2017 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 28 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

833% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 3

460% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 5

61% more funds holding

Funds holding: 41 → 66 (+25)

57% more capital invested

Capital invested by funds: $144M → $226M (+$82.2M)

9.71% more ownership

Funds ownership: 48.08% → 57.79% (+9.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+25
Holders Change %
+60.98%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
28
Increased
28
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
FCM
Farallon Capital Management
California
+$16M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.52M
3
First Manhattan
First Manhattan
New York
+$7.09M
4
BI
BVF Inc
California
+$5.22M
5
DM
Deerfield Management
New York
+$3.99M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$1.77M
2
PC
Polar Capital
United Kingdom
-$1.77M
3
SAM
Senzar Asset Management
New York
-$727K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$178K
5
NFA
Nationwide Fund Advisors
Ohio
-$77K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$63.9M +$9.52M +536,535 +21%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$42.8M – – –
FCM
3
Farallon Capital Management
California
$18.7M +$16M +900,000 New
BlackRock
4
BlackRock
New York
$10.3M +$834K +47,003 +11%
Vanguard Group
5
Vanguard Group
Pennsylvania
$10M +$2.25M +126,690 +36%
First Manhattan
6
First Manhattan
New York
$8.66M +$7.09M +399,764 +2,408%
CAM
7
Cormorant Asset Management
Massachusetts
$8.32M -$1.77M -100,000 -20%
BI
8
BVF Inc
California
$6.12M +$5.22M +294,117 New
EAM
9
Eventide Asset Management
Massachusetts
$5.72M +$2.66M +150,000 +120%
DM
10
Deerfield Management
New York
$4.68M +$3.99M +225,000 New
JP Morgan Chase
11
JP Morgan Chase
New York
$4.26M +$3.63M +204,759 New
Millennium Management
12
Millennium Management
New York
$4.01M +$982K +55,378 +40%
SAM
13
Senzar Asset Management
New York
$3.74M -$727K -41,000 -19%
AIC
14
AWM Investment Company
New York
$3.69M +$3.14M +177,212 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.91M +$481K +27,135 +24%
State Street
16
State Street
Massachusetts
$2.85M +$349K +19,661 +17%
Northern Trust
17
Northern Trust
Illinois
$2.65M +$526K +29,676 +30%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$2.5M +$2.13M +120,000 New
Jennison Associates
19
Jennison Associates
New York
$2.08M +$1.77M +100,000 New
TCM
20
Tekla Capital Management
Massachusetts
$1.72M +$1.33M +75,000 +959%
Two Sigma Investments
21
Two Sigma Investments
New York
$1.2M +$1.03M +57,776 New
PC
22
Polar Capital
United Kingdom
$1.04M -$1.77M -100,000 -67%
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
$1.04M +$887K +50,000 New
FSA
24
Franklin Street Advisors
North Carolina
$971K +$532K +30,000 +180%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$925K +$273K +15,412 +53%
1
2 3

PTGX Hedge Fund Activity: Q4 2017 in Review

66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2017, worth a combined $226M — up 57% from $144M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PTGX positions and 3 closed out — a net gain of 25 holders — while 28 added to existing stakes and 5 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $16M. The largest seller was Cormorant Asset Management, cutting an estimated $1.77M.

  • 66 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2017, up from 41 in Q3 2017.
  • Funds reported $226M of Protagonist Therapeutics stock for Q4 2017, up 57% quarter-over-quarter.
  • 28 funds opened new Protagonist Therapeutics positions in Q4 2017 and 3 closed out, a net change of +25 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $16M added.
  • The largest Protagonist Therapeutics seller in Q4 2017 was Cormorant Asset Management, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2017.